Cavernous Malformation Hemorrhagic Presentation at Diagnosis Associated with Low 25-Hydroxy-Vitamin D Level

被引:12
|
作者
Flemming, Kelly D. [1 ]
Kumar, Shivram [1 ]
Brown, Robert D., Jr. [1 ]
Singh, Ravinder J. [3 ]
Whitehead, Kevin [4 ]
McCreath, Lauren [4 ]
Lanzino, Giuseppe [2 ]
机构
[1] Mayo Clin, Dept Neurol, W8B Mayo Bldg,200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA
[3] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA
[4] Univ Utah, Dept Cardiovasc Med, Salt Lake City, UT USA
关键词
Cavernous malformation; Hemorrhage; Cavernoma; Cavernous; Angioma; Vitamin D; 25-Hydroxy-vitamin D; VITAMIN-D;
D O I
10.1159/000507789
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Cavernous malformations (CM) are angiographically occult vascular malformations that may be incidental or present with intracerebral or spinal hemorrhage, seizures, or nonhemorrhagic focal neurologic deficit (FND). Recently in vitro data have suggested vitamin D may play a role in stabilizing CCM2 endothelial cells. Little is known about the effect of vitamin D in human CM disease. Methods: Beginning in 2015, consecutive patients at our institution with radiologically confirmed CM were recruited to participate in a prospective clinical registry as well as 25-hydroxy-vitamin D study. A structured interview, survey, and examination were performed at baseline. Medical records and magnetic resonance imaging studies were reviewed and data collected included comorbid conditions, medication use, and location of CM. Standard definition of clinical hemorrhage, FND, and seizures was used. Univariate and multivariate logistic regression models were used, and OR, 95% CIs, and likelihood-ratio p values were calculated to determine the influence of the 25-hydroxy-vitamin D level on clinical presentation with hemorrhage. Results: Of 213 patients enrolled in the clinical registry between January 2015 and October 2018, 70 participated in the vitamin D study (median age: 38.3 years; 51.4% female). Of the 70 participants, 30 (42.9%) presented with hemorrhage. 25-Hydroxy-vitamin D levels were performed within 1 year of symptoms in 64.1% of patients. Patients presenting with hemorrhage had a lower 25-hydroxy-vitamin D level compared to those presenting with seizure without hemorrhage, FND, or as an incidental finding (median 25.5 ng/mL; range 11-59 hemorrhage vs. median 31.0; range 14-60, no hemorrhage; p = 0.04). After adjusting for age, month of blood draw, and body mass index, 25-hydroxy-vitamin D remained a significant predictor of hemorrhagic presentation. Brainstem location also predicted hemorrhage at presentation. Conclusion: Low 25-hydroxy-vitamin D level was more common in patients with CM presenting with hemorrhage. This study supports the potential role of modifiable factor in the initial clinical presentation of CM. Further study is needed to determine the role of vitamin D on prospective hemorrhage risk and whether supplementation may be beneficial.
引用
收藏
页码:216 / 222
页数:7
相关论文
共 50 条
  • [1] Reference values for free 25-hydroxy-vitamin D based on established total 25-hydroxy-vitamin D reference values
    Zeng, Shufei
    Chu, Chang
    Doebis, Cornelia
    von Baehr, Volker
    Hocher, Berthold
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2021, 210
  • [2] Low serum 25-hydroxy-vitamin D levels are associated with cognitive impairment in multiple sclerosis
    Spiezia, Antonio Luca
    Falco, Fabrizia
    Manganelli, Andrea
    Carotenuto, Antonio
    Petracca, Maria
    Novarella, Federica
    Iacovazzo, Carmine
    Servillo, Giuseppe
    Lanzillo, Roberta
    Morra, Vincenzo Brescia
    Moccia, Marcello
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [3] Metabolomic Profile of Serum 25-Hydroxy-Vitamin D
    Nelson, Shakira M.
    Anic, Gabriella M.
    Panagiotou, Orestis A.
    Mondul, Alison
    Weinstein, Stephanie J.
    Albanes, Demetrius
    FASEB JOURNAL, 2016, 30
  • [4] Prevalence of 25-hydroxy-vitamin D inadequacy in the UK
    Dixon, T.
    Mitchell, P.
    Beringer, T.
    Gallacher, S.
    Moniz, C.
    Patel, S.
    Pearson, G.
    Ryan, P.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : 387 - 387
  • [5] Correlation among 25-hydroxy-vitamin D assays
    Binkley, N.
    Krueger, D.
    Gemar, D.
    Drezner, M. K.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (05): : 1804 - 1808
  • [6] VITAMIN D SUPPLEMENTATION IS ASSOCIATED WITH IMPROVED SERUM 25-HYDROXY-VITAMIN D LEVELS IN CHILDREN WITH CF
    Jadin, S.
    Zhang, Z.
    Marcus, M.
    Pfeil, D.
    Seffrood, E.
    Shoff, S. M.
    Lai, H. J.
    PEDIATRIC PULMONOLOGY, 2009, : 405 - 405
  • [7] Osteoporosis in pregnancy is associated with inadequate dietary calcium intake and low stores of 25-hydroxy-vitamin D:: Presentation of a cohort of 8 cases.
    Pfeifer, M
    Pollähne, W
    Lazarescu, AD
    Minne, HW
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S558 - S558
  • [8] An improved immunoassay for the specific measurement of 25-hydroxy-vitamin D3 with no cross-reactivity to 25-hydroxy-vitamin D2.
    Li, B.
    Qvist, P.
    Christiansen, C.
    Byrjalsen, I.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S236 - S236
  • [9] Vitamin D Status and Pregnancy Complications: Serum 1,25-di-hydroxyl-Vitamin D and its Ratio to 25-hydroxy-Vitamin D are Superior Biomarkers than 25-hydroxy-Vitamin D
    Albahlol, Ibrahim A.
    Almaeen, Abdulrahman H.
    Alduraywish, Abdulrahman A.
    Dar, Umar F.
    El-Metwally, Tarek H.
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2020, 17 (18): : 3039 - 3048
  • [10] IS THE 25-HYDROXY-VITAMIN D SERUM CONCENTRATION A GOOD MARKER OF FRAILTY?
    Krams, T.
    Cesari, M.
    Guyonnet, S.
    Van Kan, G. Abellan
    Cantet, C.
    Vellas, B.
    Rolland, Y.
    JOURNAL OF NUTRITION HEALTH & AGING, 2016, 20 (10): : 1034 - 1039